Literature DB >> 22309986

A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.

Monica Fabbrini1, Chiara Sammicheli, Immaculada Margarit, Domenico Maione, Guido Grandi, Marzia Monica Giuliani, Elena Mori, Sandra Nuti.   

Abstract

Opsonophagocytosis is the primary mechanism for the clearance of Group B Streptococcus (GBS) by the host, and levels of opsonic antibodies may correlate with protection in preclinical models. A killing-based opsonophagocytosis assay (OPA), can be used to determine the functional activity of vaccine-induced GBS-specific antibodies. The assay, which measures the number of bacterial colonies surviving phagocytic killing in the presence of specific antibodies and complement, is rather expensive, time-consuming and poorly standardized. Here we describe a rapid, sensitive and reproducible fluorescent OPA assay (fOPA) based on flow cytometry analysis (FACS), which allows internalized bacteria to be distinguished from those associated to the plasma membrane of phagocytic cells. Fixed GBS were labeled with pHrodo™, a fluorescent dye which dramatically increases the emitted fluorescence at the acidic conditions present in the phagocytic endosomal compartment. Labeled bacteria were incubated with HL-60 cells differentiated to phagocytes, antibodies and complement, and then analyzed by FACS. A further improvement to our method, allowing to reduce assay variability, consisted on a step of selection of effector cells among the HL-60 population. Analysis of sera from mice immunized with different GBS vaccines revealed comparable sensitivity and specificity with the traditional killing OPA assay (kOPA), and a good correlation between the fluorescent signal of bacteria internalized by HL-60 phagocytes and killing. Remarkably, the pHrodo-based approach reduced the variability observed with other fOPA assays. The obtained data indicate the proposed fOPA as a reliable and useful tool for functional antibody assessment.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22309986     DOI: 10.1016/j.jim.2012.01.011

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Antibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border.

Authors:  Jenny Herbert; Stephen Thomas; Charlotte Brookes; Claudia Turner; Paul Turner; Francois Nosten; Kirsty Le Doare; Michael Hudson; Paul T Heath; Andrew Gorringe; Stephen Taylor
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

Review 2.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

3.  Elevated A20 contributes to age-dependent macrophage dysfunction in the lungs.

Authors:  Cecilia A Hinojosa; Ramya Akula Suresh Babu; Md M Rahman; Gabriel Fernandes; Angela R Boyd; Carlos J Orihuela
Journal:  Exp Gerontol       Date:  2014-01-17       Impact factor: 4.032

4.  Stable Expression of Modified Green Fluorescent Protein in Group B Streptococci To Enable Visualization in Experimental Systems.

Authors:  Matthew J Sullivan; Glen C Ulett
Journal:  Appl Environ Microbiol       Date:  2018-08-31       Impact factor: 4.792

Review 5.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.

Authors:  Shu Ki Tsoi; Pierre R Smeesters; Hannah R C Frost; Paul Licciardi; Andrew C Steer
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

6.  Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort.

Authors:  Kirsty Le Doare; Amadou Faal; Mustapha Jaiteh; Francess Sarfo; Stephen Taylor; Fiona Warburton; Holly Humphries; Jessica Birt; Sheikh Jarju; Saffiatou Darboe; Edward Clarke; Martin Antonio; Ebenezer Foster-Nyarko; Paul T Heath; Andrew Gorringe; Beate Kampmann
Journal:  Vaccine       Date:  2017-04-24       Impact factor: 3.641

7.  A flow cytometry-based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis.

Authors:  Marco Grasse; Ida Rosenkrands; Anja Olsen; Frank Follmann; Jes Dietrich
Journal:  Cytometry A       Date:  2018-03-07       Impact factor: 4.355

8.  Acellular Pertussis Vaccine Inhibits Bordetella pertussis Clearance from the Nasal Mucosa of Mice.

Authors:  Jana Holubová; Ondřej Staněk; Ludmila Brázdilová; Jiří Mašín; Ladislav Bumba; Andrew R Gorringe; Frances Alexander; Peter Šebo
Journal:  Vaccines (Basel)       Date:  2020-11-19

9.  Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection.

Authors:  Jiachen Huang; Aaron D Gingerich; Fredejah Royer; Amy V Paschall; Alma Pena-Briseno; Fikri Y Avci; Jarrod J Mousa
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

10.  Chemical Synthesis and Immunological Evaluation of Fragments of the Multiantennary Group-Specific Polysaccharide of Group B Streptococcus.

Authors:  Zhen Wang; Jacopo Enotarpi; Giada Buffi; Alfredo Pezzicoli; Christoph J Gstöttner; Simone Nicolardi; Evita Balducci; Monica Fabbrini; Maria Rosaria Romano; Gijsbert A van der Marel; Linda Del Bino; Roberto Adamo; Jeroen D C Codée
Journal:  JACS Au       Date:  2022-07-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.